SET and breast carcinoma: Future studies using other ER-positive cell lines, including tamoxifen-resistant cells, as well as other breast cancer subtypes, such as MDA-MB-231 and MCF 10A cells as the control groups, would be helpful in deciphering the SET–ER interacting mechanisms and to confirm that our findings are specific for ER-positive breast cancers.